Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs High-dose Imatinib in CML with Suboptimal Response
NCT00320190Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2006
- Primary completion
- Jan 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Major Molecular Response at 12 months. Started Aug 2006; status: terminated.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00320190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320190.